$ALMR

Alamar Biosciences, Inc.

Alamar Biosciences develops proteomics tools for disease detection and biomarker research. Its NULISA technology measures protein biomarkers, while its automated ARGO HT System supports sensitive, multiplexed analysis for research and diagnostics. The company sells instruments, consumables and services to academic and research institutions, biopharmaceutical companies, contract research organizations and service laboratories. Its products are used in fields such as immunology, neurology and oncology. Alamar Biosciences is based in Fremont, California.

AlphAI earnings readThird Quarter 2026 · NOV 3Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue GuidanceVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $ALMR in the last 7 days.

—
$30.4M
Qiming Corporate GP VI, Ltd.
0%
See all $ALMR insider activity →
Low

Qiming Corporate GP VI, Ltd. sold $2.9M of ALMR (indirect holdings)

Qiming Corporate GP VI, Ltd. sold 100,117 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $29.38 ($29.34–$30.63, $2.94M total) across 8 trades on 2026-11-11. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).

Qiming Corporate GP VI, Ltd. sold $3.3M of ALMR (indirect holdings)

Qiming Corporate GP VI, Ltd. sold 111,313 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at $29.89 ($3.33M total) across 4 trades on 2026-11-03. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).

ALMR sentiment & insider activity

Recent ALMR coverage spans insider activity, financial news and earnings.

In the last 30 days, ALMR insiders filed 88 SEC Form 4 transactions — no purchases and 88 sales ($30.4M). The most active reporter was Qiming Corporate GP VI, Ltd. with 88 filings.

What's driving ALMR

  • The insider sale suggests potential downside pressure on ALMR as a major shareholder reduces its position.

    SEC EDGAR · Nov 14, 2026

  • Insider sale by a 10% owner may signal modest concern, but the amount is relatively small for a micro‑cap.

    SEC EDGAR · Nov 5, 2026

  • TD Cowen reaffirmed its Buy rating for Alamar Biosciences and increased its price target to $36 from $34, suggesting a 19.1% upside from the Nov 3 close of $30.22.

    tradingview.com · Nov 4, 2026

  • The upward revision suggests modest buying pressure as the market incorporates the higher target.

    tradingview.com · Nov 4, 2026

  • Alamar Biosciences reported Q3 2026 revenue of $33.5M, up 68% YoY, driven by a 79% surge in consumables sales. The company raised its full-year outlook, citing strong biopharma customer demand and research partnerships. Gross margin improved to 61.5%, but net loss widened to $13.3M due to increased operating expenses. The stock closed at $30.22, up 4.42%, before slipping in after-hours trading.

    investing.com · Nov 3, 2026

AlphAI scores every news story that mentions ALMR with an AI model for sentiment and relevance, and aggregates insider trades from Alamar Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ALMR

Score

Qiming Corporate GP VI, Ltd. sold $2.9M of ALMR (indirect holdings)

Qiming Corporate GP VI, Ltd. sold 100,117 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $29.38 ($29.34–$30.63, $2.94M total) across 8 trades on 2026-11-11. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).

Qiming Corporate GP VI, Ltd. sold $3.3M of ALMR (indirect holdings)

Qiming Corporate GP VI, Ltd. sold 111,313 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at $29.89 ($3.33M total) across 4 trades on 2026-11-03. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).

Alamar Q3 2026 presentation: consumables surge, guidance raised

Alamar Biosciences reported Q3 2026 revenue of $33.5M, up 68% YoY, driven by a 79% surge in consumables sales. The company raised its full-year outlook, citing strong biopharma customer demand and research partnerships. Gross margin improved to 61.5%, but net loss widened to $13.3M due to increased operating expenses. The stock closed at $30.22, up 4.42%, before slipping in after-hours trading.

Qiming Corporate GP VI, Ltd. sold $5.7M of ALMR (indirect holdings)

Qiming Corporate GP VI, Ltd. sold 187,636 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $30.25 ($29.84–$33.31, $5.68M total) across 24 trades over 2026-10-30 to 2026-11-02. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).

$ALMRMedEarnings

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance FREMONT, Calif. Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection o

Qiming Corporate GP VI, Ltd. sold $6.0M of ALMR (indirect holdings)

Qiming Corporate GP VI, Ltd. sold 185,731 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $32.14 ($30.33–$33.11, $5.97M total) across 20 trades over 2026-10-27 to 2026-10-28. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).

$ALMRMedAI 8/10

Alamar Biosciences’ technology used in study detecting ALS with 98% accuracy

Alamar Biosciences (ALMR) reported that Emory University researchers used its NULISA technology to identify a 10-protein blood signature with 98.3% accuracy in detecting ALS. The study, published in Nature Communications, measured over 300 proteins, though the signature is not yet clinically validated. CEO Yuling Luo emphasized the importance of measuring low-abundance proteins.

Related tickers